ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2013, Vol. 22 ›› Issue (2): 175-179.

• 论文 • 上一篇    下一篇

腹膜透析和血液透析联合治疗终末期肾病:一种新的治疗模式

  

  • 出版日期:2013-04-28 发布日期:2013-04-29

Combination of peritoneal dialysis and hemodialysis as a new modality of treatment for end-stage renal disease

  • Online:2013-04-28 Published:2013-04-29

摘要:

摘要:行持续不卧床腹膜透析(continuous ambulatory peritoneal dialysis,CAPD)治疗的患者的残余肾功能(residual renal function,RRF)对其生存质量及生存率起到至关重要的作用。随着透析时间的延长,腹膜透析患者的残余肾功能逐渐下降或丢失出现透析不充分的症状。此外,腹膜超滤功能衰竭也是导致患者退出腹膜透析的主要原因之一。此时,选择每日的腹膜透析联合每周一次的血液透析即腹膜透析和血液透析联合治疗。可以达到清除毒素和水份的目的,从而提高患者生活质量和减少医疗费用。本文将就腹膜透析和血液透析联合治疗终末期肾病(end-stage renal disease,ESRD)这一疗法作一简述。

关键词: 关键词:腹膜透析和血液透析联合治疗 , 终末期肾病 残余肾功能

Abstract:

Abstract:
Because the contribution of residual renal function (RRF) to total solute clearance is often significant in continuous ambulatory peritoneal dialysis (CAPD), loss of RRF over time can lead to inadequate dialysis if appropriate prescription management strategies are not pursued. Additionally, declines in ultrafiltration caused by increases in peritoneal permeability may limit continuation of CAPD therapy. Peritoneal dialysis and hemodialysis (PD + HD) combination therapy (complementary dialysis therapy) is an alternative method. This therapy allows the patient to maintain daily activities, as with CAPD, while undergoing once-a-week HD supplements for the insufficient removal of solutes and water. This therapy allows for the continuation of PD without shifting to total HD in PD patients who continue to have uremic symptoms even after individualization of the PD prescription. This treatment option is psychologically more acceptable to patients and may be expected to provide such accompanying beneficial effects as peritoneal resting, improvement of QOL and reduction in medical cost. The present review aims to summarize the of PHD.